Lenalidomide in the Treatment of Multiple Myeloma

Česká verzia

Authors: K. Machálková; V. Maisnar
Authors place of work: Oddělení klinické hematologie, II. interní klinika LF UK a FN Hradec Králové
Published in the journal: Klin Onkol 2009; 22(3): 117-120
Category: Case Reports

Summary

We present the case of a 58-year old patient with relapsed multiple myeloma, in which lenalidomide was used in combination with dexamethasone after the failure of previous treatment modalities. The progression of the myeloma was clinically manifested by painful swelling of the patient’s left arm caused by an extensive osteolytic lesion of the bone. After one month of therapy with lenalidomide and dexamethasone, a significant decrease in the paraprotein level was detected. Later, the clinical finding on the left arm was normalized too and concurrently the X ray image shows the production of new bone.

Key words:
multiple myeloma – treatment – lenalidomide

Zdroje

1. Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 2008; 33(3): 219–226.

2. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus Dexamethasone for relapsed or refraktory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.

3. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med 2007; 357: 2133–2142.

4. Celgene corporation – Summary of Product Characteristics. 92 stran, poslední aktualizace 2. 5. 2008.

5. Cavo M et al. Lenalidomide in relapsed/refraktory multiple myeloma: overall survival. Leukemia Res 2008; 32 (Suppl 1): S12–S19.

6. Cavo M et al. Lenalidomide: towards a new standart in the optima management of multiple myeloma. Leukemia Res 2008; 32 (Suppl 1): S20–S24.